Skip to main content
OpenTrials
Completed

NCT Number: NCT01539850

Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102

The main objective of this study is to evaluate the LGL102 implant safety in obese to morbidly obese subjects treated with OMS102 system. The effect of the therapy on body weight changes will be also evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wolfart Klinik, Gräfelfing, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age of 18 - 60 years old at time of screening
  • BMI of 35 to 55 at time of screening
  • History of obesity ≥ 5 years
  • The subject has been under routine care of the investigator or another single physician that can supply a medical record for at least 6 months prior to enrollment
  • Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods
  • No significant weight loss (< 5%) within four months prior to enrollment as documented in the subject's medical record.
  • Successful psychological evaluation following the institution psychological evaluation protocol for bariatric surgery or successful historic assessment performed no more than 6 months prior to enrollment.
  • Glycosylated Hemoglobin; HbA1c ≤ 7.0 % at Visit 2 or historic value performed no more than 3 months prior to enrollment.
  • If taking anti-depressant medications, they must be stable for at least six months prior to enrollment
  • Willingness to refrain from using prescription, over the counter or herbal weight loss products for the duration of the trial
  • Alert, mentally competent, and able to understand and willing to comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial
  • Able to provide voluntary informed consent

Exclusion criteria

  • Any prior bariatric surgery
  • Other implanted electrical stimulation devices (e.g. pacemaker, defibrillator, neurostimulator)
  • Diagnosed with past or current psychiatric condition that may impair his/her ability to comply with the study procedures
  • Use of anti-psychotic medications
  • Diagnosed with a eating disorder such as bulimia or binge eating
  • Obesity due to an endocrinopathy (e.g. Cushing disease)
  • Insulin therapy
  • GI disease such as hiatal hernia (> 5cm), gastroparesis, esophageal motility disorders or intractable constipation.
  • Any history of peptic ulcer disease within 5 years prior to enrollment
  • History of Barrett's esophagus
  • Women who are pregnant, lactating or anticipate becoming pregnant within 24 months
  • Arthritis or other pathologies limiting physical activities that physician feels should exclude the patient from the study.
  • Cardiac history that physician feels should exclude the patient from the study.
  • Use of another investigational device or agent in the 30 days prior to enrollment
  • A history of life-threatening disease within 5 years prior to enrollment
  • Any other condition that, in the opinion of the investigator, would make the subject unsuitable for the study

Treatment and study plan

OMS102

Device

Subjects will receive implanted OMS102 System.

Other names: abiliti System

Primary outcomes

  1. Transgastric sensor site healing

    Time frame: 3 months

    Food sensor transgastric site healing will be evaluated during a gastro endoscopy exam performed three months after implant.

Secondary outcomes

  1. Excess weight loss

    Time frame: 3, 6, and 12 months

    Percentage of excess body weight loss (%EWL) compared to baseline.

  2. Safety Evaluation

    Time frame: 3, 6, and 12 months

    Occurrence and severity of all adverse events

  3. Quality of Life

    Time frame: 3, 6 and 12 months

    Evaluation of the quality of life using the Moorehead-Ardelt II questionnaire

  4. Eating Behavior

    Time frame: 3, 6 and 12 months

    Eating behavior (cognitive restraint, uncontrolled eating, and emotional eating) using the Three Factor Eating Questionnaire (TFEQ)

  5. Comorbid Conditions

    Time frame: 3, 6 and 12 months

    Any reduction of blood pressure and oral diabetes medications

Sponsors and collaborators

Lead sponsor

IntraPace, Inc

Industry

Registry information

Official study title

Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102. A Prospective Multicenter Study

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Feb 28, 2012
Registry last updated
Feb 28, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.